Skip to content

Pilot Trial of External Warming in Septic Patients

Pilot Randomized Trial of External Warming in Critically Ill Adult Septic Patients

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02706275
Enrollment
60
Registered
2016-03-11
Start date
2016-03-31
Completion date
2019-05-12
Last updated
2020-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Sepsis

Brief summary

The purpose of this study is to determine whether externally warming critically ill afebrile adult septic patients will improve indices of immune function and/or clinical outcomes.

Interventions

OTHERExternal warming

External warming via forced air warming to a goal body temperature 1.5°C greater than the baseline minimum temperature (within previous 24 hours) for 48 hours

Sponsors

Washington University School of Medicine
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Admitted to a surgical or medical intensive care unit * Age greater than 18 years * Diagnosis of sepsis within 24 hours of enrollment * Requirement for mechanical ventilation with expected duration of mechanical ventilation \> 48 hours * Goal Richmond Agitation Sedation Scale (RASS) \< 0 * Maximum baseline temperature (within previous 24 hours) \< 38.3°C

Exclusion criteria

* Treatment with chemotherapy within 6 months of enrollment * Treatment with corticosteroids at a dose \> 300 mg/day hydrocortisone (or equivalent) * History of solid organ transplant on any immunosuppression medication * History of immunological disease * History of chronic infection with hepatitis B or C virus * History of acute stroke, acute coronary syndrome, or severe head injury requiring osmotic therapy within 7 days prior to enrollment * History of multiple sclerosis * Contraindications to both bladder or esophageal core temperature monitors or to forced air warming blankets * Moribund status * Sepsis without source control

Design outcomes

Primary

MeasureTime frame
Monocyte human leukocyte antigen (mHLA-DR) expression48 hours hours following the start of the intervention period

Secondary

MeasureTime frameDescription
Interferon (IFN)-gamma production48 hours following the start of the intervention period
Number of patients who acquire nosocomial infections30 days after diagnosis of sepsisNumber of patients who develop a nosocomial infection (defined as a new infection diagnosed greater than 48 hours after the original sepsis diagnosis) within 30 days of the sepsis diagnosis
Mortality28 days
Number of patients in whom the intervention is stopped early secondary to hemodynamic changes related to the interventionThrough study completion, 2 years

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 25, 2026